Valerio Therapeutics (FRA:C4X) Tariff Resilience Score: 0/10 (As of Jul. 11, 2026)


FRA:C4X Valerio Therapeutics FRA:C4X
31 GF Score
Price €0.44
GF Value €0.07
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Valerio Therapeutics Tariff Resilience Score?

Valerio Therapeutics has the Tariff Resilience Score of 0, which implies that the company might have .

Valerio Therapeutics has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Valerio Therapeutics might have .

Valerio Therapeutics  (FRA:C4X) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Valerio Therapeutics Tariff Resilience Score Related Terms

FRA:C4X
31GF Score
Valerio Therapeutics FRA:C4X
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valerio Therapeutics (FRA:C4X) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.44 is trading 528.6% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:C4X:

  • Tariff Resilience Score: 0
  • GF Value™: €0.07 vs. price of €0.44 (528.6% above fair value)
  • GF Score™: 31/100 with 6 warning signs

No single metric tells the full story. See the FRA:C4X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKALVIO:France
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
31GF Score

Get the complete analysis for FRA:C4X

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.44
Price
€0.07
GF Value